Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 2802

Sort by

Sort Order Select

Journal Articles

CLL-IPI: valid in the era of oral inhibitors?

Nadine Kutsch

Blood (2021) 138 (2): 106–107.

https://doi.org/10.1182/blood.2021011937

Published: 2021

Journal Articles

Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results

Murielle Roussel, Valerie Lauwers-Cances, Soraya Wuilleme, Karim Belhadj, Salomon Manier, Laurent Garderet, Martine Escoffre-Barbe, Clara Mariette, Lotfi Benboubker, Denis Caillot, Cécile Sonntag, Cyrille Touzeau, Jehan Dupuis, Philippe Moreau, Xavier Leleu, Thierry Facon, Benjamin Hébraud, Jill Corre, Michel Attal

Blood (2021) 138 (2): 113–121.

https://doi.org/10.1182/blood.2021010744

Published: 2021

Journal Articles

IKZF1 alterations predict poor prognosis in adult and pediatric T-ALL

Mathieu Simonin, Ludovic Lhermitte, Marie-Emilie Dourthe, Etienne Lengliné, Carlos Graux, Nathalie Grardel, Jean-Michel Cayuela, Isabelle Arnoux, Virginie Gandemer, Norbert Ifrah, Hervé Dombret, André Baruchel, Elizabeth Macintyre, Arnaud Petit, Nicolas Boissel, Vahid Asnafi

Blood (2021) 137 (12): 1690–1694.

https://doi.org/10.1182/blood.2020007959

Published: 2021

Includes: Supplemental data

Journal Articles

Minimal residual disease quantification in ovarian tissue collected from patients in complete remission of acute leukemia

Florian Chevillon, Emmanuelle Clappier, Chloé Arfeuille, Jean-Michel Cayuela, Jean Hugues Dalle, Rathana Kim, Aurélie Caye-Eude, Céline Chalas, Chrystelle Abdo, Véronique Drouineaud, Régis Peffault de Latour, Marion Alcantara, Madalina Uzunov, Michael Degaud, Véronique Meignin, Hervé Dombret, Nicolas Boissel, Catherine Poirot, Nathalie Dhédin

Blood (2021) 137 (12): 1697–1701.

https://doi.org/10.1182/blood.2020007782

Published: 2021

Includes: Supplemental data

Journal Articles

A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study)

Blood (2021) 137 (12): 1582–1590.

https://doi.org/10.1182/blood.2020007848

Published: 2021

Includes: Supplemental data

Journal Articles

A fixed-duration, measurable residual disease–guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial

Blood (2021) 137 (8): 1019–1023.

https://doi.org/10.1182/blood.2020008164

Published: 2021

Includes: Supplemental data

Journal Articles

Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure

Jordan Gauthier, Alexandre V. Hirayama, Janaki Purushe, Kevin A. Hay, James Lymp, Daniel H. Li, Cecilia C. S. Yeung, Alyssa Sheih, Barbara S. Pender, Reed M. Hawkins, Aesha Vakil, Tinh-Doan Phi, Rachel N. Steinmetz, Mazyar Shadman, Stanley R. Riddell, David G. Maloney, Cameron J. Turtle

Blood (2020) 135 (19): 1650–1660.

https://doi.org/10.1182/blood.2019002936

Published: 2020

Includes: Supplemental data

Journal Articles

Reduced–dose intensity therapy for pediatric lymphoblastic leukemia: long-term results of the Recife RELLA05 pilot study

Francisco Pedrosa, Elaine Coustan-Smith, Yinmei Zhou, Cheng Cheng, Arli Pedrosa, Mecneide Mendes Lins, Marcia Pedrosa, Norma Lucena-Silva, Alessandra Maria de Luna Ramos, Ester Vinhas, Gaston K. Rivera, Dario Campana, Raul C. Ribeiro

Blood (2020) 135 (17): 1458–1466.

https://doi.org/10.1182/blood.2019004215

Published: 2020

Includes: Supplemental data

Journal Articles

Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy

Philip A. Thompson, Jaya Srivastava, Christine Peterson, Paolo Strati, Jeffrey L. Jorgensen, Tyler Hether, Michael J. Keating, Susan M. O’Brien, Alessandra Ferrajoli, Jan A. Burger, Zeev Estrov, Nitin Jain, William G. Wierda

Blood (2019) 134 (22): 1951–1959.

https://doi.org/10.1182/blood.2019001077

Published: 2019

Includes: Supplemental data

Journal Articles

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)

Saad Z. Usmani, MDMBBS, Hang Quach, MD, María-Victoria Mateos, Ola Landgren, MD PhD, Xavier Leleu, MD PhD, David S. Siegel, Katja Weisel, Hui Yang, Zandra K. Klippel, MD, Anita Zahlten-Kumeli, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_2): LBA-6.

https://doi.org/10.1182/blood-2019-132629

Published: 2019

Journal Articles

A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk (HR/IR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs) Demonstrates Superior Efficacy and Tolerability of Blinatumomab: A Report from Children's Oncology Group Study AALL1331

Patrick A. Brown, MD, Lingyun Ji, PhD, Xinxin Xu, MS, Meenakshi Devidas, PhD, Laura Hogan, MD, Michael J. Borowitz, MD PhD, Elizabeth A. Raetz, MD, Gerhard Zugmaier, Elad Sharon, MD MPH, Lia Gore, MD, James A. Whitlock, MD, Michael A. Pulsipher, MD, Stephen P. Hunger, MD, Mignon L. Loh, MD

Blood (2019) 134 (Supplement_2): LBA-1.

https://doi.org/10.1182/blood-2019-132435

Published: 2019

Journal Articles

Phase 1 Trial of the Safety and Efficacy of Fully Human Anti-Bcma CAR T Cells in Relapsed/Refractory Multiple Myeloma

Blood (2019) 134 (Supplement_1): 4435.

https://doi.org/10.1182/blood-2019-126104

Published: 2019

Journal Articles

Targeted Mass Spectrometry-Based Serum M-Protein Monitoring for Early Relapse Detection

Zac McDonald, PhD, Mariya Liyasova, PhD, Paul Taylor, Xin Xu, Kathleen Gorospe, Chenyu Yao, Qixin Liu, Liqiang Yang, PhD, Bin Ma, PhD, Jesus Piza, MD, Donna E Reece, MD, Suzanne Trudel, MD

Blood (2019) 134 (Supplement_1): 4347.

https://doi.org/10.1182/blood-2019-130251

Published: 2019

Journal Articles

Evaluation of Biomarkers As Predictors of Blinatumomab Toxicity and Real-World Management of Blinatumomab Toxicity in B-Acute Lymphoblastic Leukemia Patients

Amber C. King, PharmD, BCOP, Jae H. Park, MD, Mark B. Geyer, MD

Blood (2019) 134 (Supplement_1): 3887.

https://doi.org/10.1182/blood-2019-128506

Published: 2019

Journal Articles

Fludarabine, High Dose Cytarabine and Idarubicin-Based Induction Is Highly Effective in Young AML Patients with Concomitant NPM1 and FLT3-ITD Mutation Irrespectively of FLT3-ITD Allelic Burden

Blood (2019) 134 (Supplement_1): 3828.

https://doi.org/10.1182/blood-2019-131303

Published: 2019

Journal Articles

Interim Results of a First in Man Study with the Fc-Optimized FLT3 Antibody Flysyn for Treatment of Acute Myeloid Leukemia with Minimal Residual Disease

Sabine Kayser, MD, Jonas S. Heitmann, MD, Daniela Dörfel, MD, Felicitas Thol, MD, Michael Heuser, MD, Melanie Märklin, PhD, Carsten Müller-Tidow, MD, Martin Steiner, Ludger Grosse-Hovest, Gundram Jung, MD, Richard F. Schlenk, MD, Helmut R. Salih, MD

Blood (2019) 134 (Supplement_1): 3928.

https://doi.org/10.1182/blood-2019-125327

Published: 2019

Journal Articles

Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (Mini-hyper-CVD) with or without Blinatumomab Is Highly Effective in Patients (pts) with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in First Relapse

Blood (2019) 134 (Supplement_1): 3806.

https://doi.org/10.1182/blood-2019-129018

Published: 2019

Journal Articles

Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age ≤ 65 years) with Mantle Cell Lymphoma (MCL) - Results of Phase-II Window-1 Clinical Trial

Blood (2019) 134 (Supplement_1): 3987.

https://doi.org/10.1182/blood-2019-126044

Published: 2019

Journal Articles

Frontline Treatment with Ibrutinib with Rituximab (IR) Combination Is Highly Effective in Elderly (≥65 years) Patients with Mantle Cell Lymphoma (MCL) - Results from a Phase II Trial

Blood (2019) 134 (Supplement_1): 3988.

https://doi.org/10.1182/blood-2019-125800

Published: 2019

Journal Articles

A Phase 1/2 Study of Quizartinib (Q) in Combination with Re-Induction Chemotherapy and As Single-Agent Continuation Therapy in Pediatric and Young Adult Patients with Relapsed/Refractory (R/R) FLT3 -ITD Acute Myeloid Leukemia (AML)

C. Michel Zwaan, MD PhD, Edward Anders Kolb, MD, Derek E. Mires, PharmD, Michele Vigliotti, PharmD, Jingdong Xie, PhD, Pamela Downs, BS, Arthur P DeCillis, MD MS, Cara A Rabik, MD PhD, Todd M Cooper, DO

Blood (2019) 134 (Supplement_1): 3937.

https://doi.org/10.1182/blood-2019-121736

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

CLL-IPI: valid in the era of oral inhibitors?

Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results

IKZF1 alterations predict poor prognosis in adult and pediatric T-ALL

Minimal residual disease quantification in ovarian tissue collected from patients in complete remission of acute leukemia

A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study)

A fixed-duration, measurable residual disease–guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial

Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure

Reduced–dose intensity therapy for pediatric lymphoblastic leukemia: long-term results of the Recife RELLA05 pilot study

Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)

Phase 1 Trial of the Safety and Efficacy of Fully Human Anti-Bcma CAR T Cells in Relapsed/Refractory Multiple Myeloma

Targeted Mass Spectrometry-Based Serum M-Protein Monitoring for Early Relapse Detection

Evaluation of Biomarkers As Predictors of Blinatumomab Toxicity and Real-World Management of Blinatumomab Toxicity in B-Acute Lymphoblastic Leukemia Patients

Fludarabine, High Dose Cytarabine and Idarubicin-Based Induction Is Highly Effective in Young AML Patients with Concomitant NPM1 and FLT3-ITD Mutation Irrespectively of FLT3-ITD Allelic Burden

Interim Results of a First in Man Study with the Fc-Optimized FLT3 Antibody Flysyn for Treatment of Acute Myeloid Leukemia with Minimal Residual Disease

Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (Mini-hyper-CVD) with or without Blinatumomab Is Highly Effective in Patients (pts) with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in First Relapse

Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age ≤ 65 years) with Mantle Cell Lymphoma (MCL) - Results of Phase-II Window-1 Clinical Trial

Frontline Treatment with Ibrutinib with Rituximab (IR) Combination Is Highly Effective in Elderly (≥65 years) Patients with Mantle Cell Lymphoma (MCL) - Results from a Phase II Trial

A Phase 1/2 Study of Quizartinib (Q) in Combination with Re-Induction Chemotherapy and As Single-Agent Continuation Therapy in Pediatric and Young Adult Patients with Relapsed/Refractory (R/R) FLT3 -ITD Acute Myeloid Leukemia (AML)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only